简介内容:CHMFL-ABL-053 (Compound 18a) is a potent, selective, and orally available BCR-ABL, SRC and p38 kinase inhibitor with IC 50 values of 70, 90 and 62 nM against ABL1, SRC and p38, respectively. CHMFL-ABL-053 is a potentially useful drug candidate for Chronic Myeloid Leukemia(CML)[1].